Physician profile
Usha Sudindranath
NPI 1578638862
$3,466.88
in general payments reported to CMS, 2019-2025
20 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $560 · 2021: $263 · 2022: $670 · 2023: $393 · 2024: $837 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.55 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $642.47 | 2019-2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $457.32 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $435.61 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $354.82 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $300.86 | 2020-2025 | Ingrezza |
| Indivior INC. | $231.05 | 2019-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.85 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $171.29 | 2019-2020 | |
| Lundbeck LLC | $150.57 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $135.10 | 2020-2021 | |
| Abbvie INC. | $101.39 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $97.22 | 2020-2024 | Invega Sustenna |
| Axsome Therapeutics, INC. | $73.76 | 2022-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $45.98 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $24.25 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $22.94 | 2019 | |
| Noven Therapeutics, LLC | $14.78 | 2024 | Secuado |
| Merck Sharp & Dohme LLC | $14.05 | 2023 | Belsomra |
| Allergan, INC. | $11.16 | 2019 | |
| Corium, LLC | $8.41 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Sudindranath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.